BioSpace News Archive

Drug Development

Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development

Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.

April 12, 2024
·
5 min read
·
Kate Goodwin
AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates

This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.

April 12, 2024
·
3 min read
·
Greg Slabodkin
Top Q1 Series A Investments Highlight VC Rebound in Biopharma

Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.

April 12, 2024
·
4 min read
·
Neil Versel
Policy

EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm

The European Medicines Agency on Friday said it found no evidence linking GLP-1 receptor agonists with suicidal thoughts and actions, following a review of patients taking Novo Nordisk’s semaglutide and liraglutide, and Eli Lilly’s dulaglutide and AstraZeneca’s exenatide.

April 12, 2024
·
2 min read
·
Tristan Manalac
Policy

Lilly Suffers Legal Loss in Tirzepatide Case Against Compounding Pharmacy

Florida District Judge Roy Altman earlier this week ruled against Eli Lilly, finding that the drugmaker cannot use state law to block reformulated versions of its blockbuster weight-loss and diabetes medication tirzepatide.

April 12, 2024
·
2 min read
·
Tristan Manalac
Job Trends

Fujifilm Pumps $1.2B into CDMO Capacity in North Carolina, Eyes 680 New Jobs by 2031

The global contract development and manufacturing organization is investing $1.2 billion to boost production capabilities at its Holly Springs, North Carolina, site including mammalian cell culture bioreactors.

April 12, 2024
·
2 min read
·
Tristan Manalac
Policy

EC Approves Illumina’s Plan to Divest Cancer Diagnostics Maker Grail

After a years-long antitrust battle, the European Commission on Friday approved Illumina’s plans to divest Grail. However, Illumina said while there is “an agreement with the EC on specific divestment options” that “does not mean the method of divestment has been finalized.”

April 12, 2024
·
2 min read
·
Tyler Patchen
FDA

AstraZeneca Expands Fasenra’s Label to Younger Children with Severe Asthma

The FDA on Thursday approved the label expansion of AstraZeneca’s Fasenra as an add-on maintenance treatment for severe eosinophilic asthma in patients six to 11 years of age.

April 12, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Enlivex’s Stock Plummets 50% on Phase II Sepsis Results for Cell Therapy

Investors were disappointed in data from a mid-stage study of Enlivex Therapeutics’ Allocetra cell therapy for the treatment of sepsis. The Israeli company is considering a follow-on trial in sepsis caused by urinary tract infection.

April 12, 2024
·
2 min read
·
Kate Goodwin
Genetown

Seismic Therapeutic Presents Preclinical Data on S-1117, its Novel Pan-IgG Protease Addressing Multiple Pathogenic Mechanisms in Autoimmune Disease, at American Academy of Neurology (AAN) 2024

Seismic Therapeutic, Inc today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) 2024 annual meeting in Denver.

April 12, 2024
·
3 min read